Loading
Nanoplatforms for Cancer Theranostics / Ferroptosis and Cancer Prognosis · Journal article
Journal of Nanobiotechnology · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study describing engineering of a nanoparticle (VEP@HA-NO) designed to simultaneously induce ferroptosis and disulfidptosis-like cell death by disrupting glucose homeostasis and modulating the SLC7A11/GSH/GPX4 axis. The work presents a theoretical strategy and proof-of-concept but lacks quantitative efficacy data, in vivo validation, or clinical evidence.
Journal article. Cancer cells (cell type and model system not specified); no human subjects or patient data reported. Intervention: Engineered nanoparticle (VEP@HA-NO) combining epigallocatechin gallate (EGCG), vanadium, paclitaxel, and hyaluronic acid-NO conjugate to induce glucose deprivation and modulate SLC7A11/GSH/GPX4 axis.
VEP@HA-NO coordinates epigallocatechin gallate (EGCG) with vanadium for paclitaxel loading to modulate SLC7A11/GSH/GPX4 axis EGCG inhibits GLUT1 to block glucose influx, limiting NADPH supply and suppressing cystine/cysteine conversion Cystine accumulation provokes disulfide stress while cysteine deficiency impairs GSH biosynthesis and deactivates GPX4
No in vivo tumor growth, survival, or pharmacokinetic data provided
This preliminary work describes a novel nanoparticle design strategy but does not yet provide evidence suitable for clinical translation. Substantial additional in vivo efficacy, toxicity, and mechanism validation work would be needed before clinical consideration.
This is a mechanistic in vitro study of a engineered nanoparticle system demonstrating proof-of-concept for dual cell death pathways; it lacks clinical outcome data, in vivo efficacy evidence, or comparison to standard therapy.
As stated by the source record.
This preliminary work describes a novel nanoparticle design strategy but does not yet provide evidence suitable for clinical translation. Substantial additional in vivo efficacy, toxicity, and mechanism validation work would be needed before clinical consideration.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Disulfidptosis and ferroptosis are emerging regulated cell death modalities for cancer therapy, both critically reliant on intracellular cystine/cysteine conversion along SLC7A11/glutathione/glutathione peroxidase 4 (SLC7A11/GSH/GPX4) antioxidant axis. However, their synchronous activation is hindered by the opposing roles of cystine transport. Leveraging their metabolic crosstalk, disrupting glucose homeostasis to induce nicotinamide adenine dinucleotide phosphate (NADPH) deficiency offers a rational strategy to overcome this limitation. Herein, we engineered a nanoinducer (VEP@HA-NO) by coordinating epigallocatechin gallate (EGCG) with vanadium for paclitaxel loading, followed by coating with a hyaluronic acid (HA)-NO conjugate to regulate SLC7A11/GSH/GPX4 axis. In this system, EGCG functions as glucose transport 1 (GLUT1) inhibitor, blocking glucose influx, limiting NADPH supply and suppressing cystine/cysteine conversion. This metabolic intervention yields two convergent effects: cystine accumulation provokes disulfide stress, while cysteine deficiency impairs GSH biosynthesis and deactivates GPX4, synchronously inducing disulfidptosis-like cell death and amplifying ferroptosis, thereby resolving the contradictory roles of cystine transport. Concurrently, vanadium delivery consumes GSH and generates hydroxyl radicals, further potentiating ferroptosis. Moreover, VEP@HA-NO inhibits cancer stem cells stemness and M2 macrophages polarization while enhancing T cells activity. Collectively, this work establishes a novel paradigm for simultaneously triggering ferroptosis/disulfidptosis-like cell death by disrupting glucose homeostasis, offering a promising strategy for enhanced antitumor therapy. Schematic illustration of the multifaceted therapeutic mechanisms mediated by VEP@HA-NO.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.